Expression of Interest for Observational Trials · Mind Medicine Australia
Mind Medicine Australia logo Menu

Expression of Interest for Observational Trials

Mind Medicine Australia (MMA) is excited to announce a new fund to support the development of observational trials into psychedelic-assisted therapies to treat a range of mental illnesses. The initial commitment of funding of $1 million will be provided by the Hunt Family Foundation with additional funding sought from other philanthropists.

Applications will be assessed and managed by relevant members of the scientific and clinical advisory panel of Mind Medicine Australia chaired by Professor David Nutt, Head of Neuropsychopharmacology at Imperial College London. Please see members of the Review Committee below.

Applications will be reviewed in order of receipt.

This EOI is for Researchers, Institutions, Academics etc. seeking funding to conduct observational trials into psychedelic-assisted therapies.

Deadline for first round of applications is Friday 21 October 2022.

"*" indicates required fields

Name*
Address*
Please include summary details of your proposed observational trial (primary illness/conditions being investigated, number of participants, whether proposal is to use psilocybin or MDMA or to have separate streams comparing the use of MDMA and psilocybin and/or other treatments, type and duration of therapy, principal investigator(s) and other key personnel, expected length of trial in days once funding is secured, restrictions on patient eligibility, what data you hope to capture, likely clinical location(s), any other key aspects of the trial that you would like us to consider). Max 500 words.
What makes the proposed principal investigator(s) the ideal person/people to lead this trial? Who else is involved and/or supporting the proposed trial? Have the proposed principal investigator(s) been involved in any other psychedelic-assisted therapy trials and what is their knowledge and experience in this field and in clinical/observational trials generally? Max 300 words plus CVs attached for all key personnel.
Drop files here or
Accepted file types: pdf, doc, docx, Max. file size: 10 MB, Max. files: 10.
    Please provide by number of days allowed for each segment from commitment of funds through to publication of data. Please note that we would like to see a sense of urgency given the magnitude of the mental health crisis in Australia and that we should also be able to help you secure the necessary GMP pharmaceutical medicine supplies.
    Who will act as the Sponsor of the Trial and details of their proposed involvement? Max 100 words.
    This should include all sources of funding including any contributions from you and your organisation and other funding sources and proposed use of funds. How much are you seeking from our grant fund?
    What else would you like to share with us? (max 150 words)
    Drop files here or
    Accepted file types: pdf, doc, docx, Max. file size: 10 MB, Max. files: 10.
      I understand that submission of this form does not confirm my eligibility for funding, and that, upon submission of this form, I will receive more information about my eligibility, the program and its requirements.*
      I declare that the information in this EOI is true and correct at the time of submission and I am authorised to submit the application on behalf of the organisation.*

      The information on this form is being collected by MMA. The information is being collected for the legitimate interest of assessing your EOI for funding under this program. The information will be used by authorised staff for the purpose for which it was collected and will be protected against unauthorised access and use.

      Deadline for first round of applications is Friday 21 October 2022.

      This field is for validation purposes and should be left unchanged.

      Review Committee

      Prof David Nutt (UK)

      BA, MB BChir, MRCP, MA, DM, MRC Psych, FRCPsych, FMedSci, FRCP, FSB

      Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London and the Chair of Drug Science.

      Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.

      Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.

      He was previously Chair of the UK Advisory Council on the Misuse of Drugs.

      Anouk Koopman-Daemen

      MSc, BSc

      Anouk is the founder and lead consultant of AK Clinical Research, a niche Clinical Research Organisation based in Melbourne, Australia, providing specialised expertise in all aspects of clinical trial management and monitoring. She is supporting pharma, biotech, CRO as well as academic investigator-initiated projects.

      Anouk has close to 20 years of International Pharmaceutical Clinical Trials Experience, including 15 years of Clinical Project leadership in Australia/New Zealand. She worked on a multitude of trials in Asia-Pacific and the Netherlands across a variety of therapeutic areas, including Respiratory, Neurology, Cardiovascular, Haematology, Endocrinology, Gastrointestinal, Oncology, and Nephrology. She has been a strong contributor in various products across the entire clinical trial life span from phase I until IV.

      Michael Kornhauser

      BPHARM (HONS)

      Michael Kornhauser’s research has focussed on psychiatric and neurodenegerative diseases for close to a decade. His aim is to help develop and make available new therapies for people suffering from conditions which are currently poorly managed. As the National Head of Clinical Trial Research at HammondCare, Michael has been at the forefront of ground-breaking Alzheimer’s Disease research and has had the opportunity to be part of unique pre-clinical and clinical trial projects.

      His prior role as the Director of Clinical Trial Research at Monash Alfred Psychiatry Research Centre saw him negotiate every aspect of the clinical development process and facilitated collaboration with both big pharma and small biotech in order to bring game changing new therapies to the public. His research knowledge and experience has seen him repeatedly invited to present guest lectures at universities, the most recent being Monash University and Australian Christian University.

      Dr Eli Kotler

      MBBS MPM FRANZCP Cert. Old Age Psych. AFRACMA

      Eli is a consultant psychiatrist, holds an academic position at Monash University through the Alfred Psychiatry Research Centre, and is the medical director of Malvern Private Hospital, the first addiction hospital in Australia. He is a member of the Australasian Professional Society on Alcohol and other Drugs (APSAD). Clinically, Eli is interested in the deep connections between trauma and addiction and works within a neuro-psychoanalytic framework. Eli has overseen the development of a clinical program for addictions focused on trauma, particularly developmental trauma. This has led to an interest in medication-assisted trauma therapy. Eli worked for many years researching neurodegenerative diseases and was the principle investigator on numerous trials for novel therapeutics. He is founding member of the Melbourne Neuropsychoanalytic Group and welcomes new members. Through involvement with Monash University, Eli oversees the addiction rotation for medical students.

      Eli graduated from the first intake of the Certificate in Psychedelic-Assisted Therapies (CPAT) in June 2021. He has also been recently appointed as the Principal Investigator to lead Emyria’s upcoming MDMA trial.

      Subscribe to our newsletter

      Stay in touch with Mind Medicine Australia:

      ×